Patents by Inventor Jill Wood

Jill Wood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES
    Publication number: 20240043473
    Abstract: Provided are compositions and methods for treating progressive neurological childhood symptoms and conditions associated with lysosomal storage disorders (LSD) such as neurological mucopolysaccharidoses. The compositions may include nootropic peptides such as Semax, which can be N-terminally acetylated and/or C-terminally amidated. The peptides can be effectively delivered by intranasal administration into the brain parenchyma, where they exert a neuroprotective and anti-inflammatory effect and delay or restore neuropathophysiological defects such as neuropsychiatric problems, developmental delays, mental retardation and dementia.
    Type: Application
    Filed: February 9, 2022
    Publication date: February 8, 2024
    Inventors: Jill WOOD, Alexey PSHEZHETSKY, Poulomee BOSE
  • Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
    Patent number: 8859572
    Abstract: This invention relates to novel sulfone 2I3-dihydroimidazo[1 l2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: October 14, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Martin F. Hentemann, William Scott, Jill Wood, Jeffrey Johnson, Aniko Redman, Ann-Marie Bullion, Leatte Guernon
  • SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
    Publication number: 20130261113
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 3, 2013
    Inventors: Martin HENTEMANN, Jill WOOD, William SCOTT, Martin MICHELS, Ann-Marie CAMPBELL, Ann BULLION, Ronald ROWLEY, Aniko REDMAN
  • Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
    Patent number: 8466283
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: June 18, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman
  • INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
    Publication number: 20120149706
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 21, 2012
    Publication date: June 14, 2012
    Inventors: Jacques DUMAS, Uday KHIRE, Timothy B. Lowinger, Holger PAULSEN, Bernd RIEDL, Willian J. SCOTT, Roger A. SMITH, Jill WOOD, Holia HATOUM-MOKDAD, Wendy LEE, Aniko REDMAN, Jeffrey JOHNSON, Robert SIBLEY
  • INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
    Publication number: 20120046290
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 23, 2012
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill Wood, Holia Hatoum-Mokdad, Wendy Lee, Aniko Redman, Jeffrey Johnson, Robert Sibley
  • SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS
    Publication number: 20110190281
    Abstract: This invention relates to novel sulfone 2I3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 13, 2009
    Publication date: August 4, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Martin Hentemann, William Scott, Jill Wood, Jeffrey Johnson, Aniko Redman, Ann-Marie Bullion, Leatte Guernon
  • Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis
    Publication number: 20110083984
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 5, 2007
    Publication date: April 14, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman
  • Hydroxy, ?-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors
    Patent number: 7528255
    Abstract: The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula wherein, Y is NHR Hal is chlorine or bromine, R is H, CH3 or CH2OH, and X1 to X7 are each, independently, H, OH or —OC(O)C1-C4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X1 to X7 is OH or —OC(O)C1-C4 alkyl.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: May 5, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, William Scott, Roger Smith, Jill Wood
  • Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
    Publication number: 20080153823
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: December 13, 2007
    Publication date: June 26, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
  • Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
    Publication number: 20080032979
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 27, 2007
    Publication date: February 7, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, Scott William, Roger Smith, Jill Wood, Mary-Katherine Monahan, Reink Natero, Joel Renick, Robert Sibley
  • omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors
    Publication number: 20080027061
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 27, 2007
    Publication date: January 31, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, William Scott, Roger Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
  • INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
    Publication number: 20080009527
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,
    Type: Application
    Filed: June 26, 2007
    Publication date: January 10, 2008
    Inventors: Jacques Dumas, Uday Khire, Timothy Lowinger, Bernard Riedl, William Scott, Roger Smith, Jill Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
    Publication number: 20070244120
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: June 25, 2007
    Publication date: October 18, 2007
    Inventors: Jacques Dumas, Uday Khire, Timothy Lowinger, Holger Paulsen, Bernd Riedl, William Scott, Roger Smith, Jill Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Wendy Lee, Aniko Redman, Robert Sibley, Joel Renick
  • Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions
    Publication number: 20070213339
    Abstract: Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.
    Type: Application
    Filed: March 31, 2005
    Publication date: September 13, 2007
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Uday Khire, Xiao-Gao Liu, Dhanapalan Nagarathnam, Jill Wood, Lei Wang, Donglei Liu, Jin Zhao, Leatte Guernon, Lei Zhang
  • 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    Publication number: 20060189609
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 24, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William Bullock, David Gunn, Qingjie Liu, Sidney Liang, Donglei Liu, Steven Magnuson, Tindy Li, Eric Mull, Jill Wood, Ning Qi
  • Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
    Publication number: 20060019990
    Abstract: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: June 22, 2005
    Publication date: January 26, 2006
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David Gunn, Timotthy Lowinger, William Scott, Roger Smith, Jill Wood
  • Raf kinase inhibitors
    Publication number: 20050256174
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: June 10, 2005
    Publication date: November 17, 2005
    Inventors: Jill Wood, Hanno Wild, Daniel Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger Smith, Cheri Blum
  • Radiation curable ink jet ink compositions
    Patent number: 6593390
    Abstract: A radiation curable ink jet ink having a viscosity not greater than 35 mPa.s at 30° C. and comprising a colorant component, a diluent consisting essentially of reactive liquid material and, optionally, at least one photopolymerization catalyst and wherein the reactive liquid material is formed of both monofunctional and polyfunctional material and comprises 5 to 30% by weight of at least one oligomer.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: July 15, 2003
    Assignee: XAAR Technology Limited
    Inventors: Steve Johnson, Jill Woods
  • Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
    Patent number: RE46856
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: May 22, 2018
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman